Hu Yang, Liu Na, Zhang Ping, Pan Chao, Zhang Youping, Tang Yingxin, Deng Hong, Aimaiti Miribanu, Zhang Ye, Zhou Houguang, Wu Guofeng, Tang Zhouping
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
Department of Geriatrics Neurology, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China.
Mol Neurobiol. 2016 Oct;53(8):5269-77. doi: 10.1007/s12035-015-9441-6. Epub 2015 Sep 26.
To comprehensively evaluate the therapeutic effects on both functional and structural outcomes, we performed a meta-analysis of preclinical data on stem cell therapy in intracranial hemorrhage, thus providing optimal evidence and instruction for clinical translation. We searched online databases to identify eligible studies based on unmodified stem cell transplantation in intracranial hemorrhage (ICH). From each study, we extracted data regarding neurobehavioral and histological outcomes in order to analyze the comprehensive effective sizes according to the most important clinical parameters (seven indices) and to explore any potential correlation through meta-regression. We analyzed 40 eligible studies including 1021 animals and found a significant improvement in both behavioral and structural outcomes with the median effect size of 1.77 for modified Neurological Severity Score, 1.16 for the modified placement test, 1.82 for the rotarod test, and 1.24 for tissue loss reduction. The meta-regression results revealed that intracerebral administration was the most effective for behavioral and structural recovery post-ICH; mesenchymal stem cells shared comparable therapeutic effects with neural stem cells. Delayed therapy, applied more than 1 week after ICH, showed the greatest improvement of structural outcomes. Stem cell therapy showed significant improvement on behavioral and structural outcomes of ICH animals with relatively large effect sizes. However, the practical efficacy of the therapy is likely to be lower considering poor study quality and non-negligible publication bias. Further, future research should interpret animal results cautiously considering the limited internal and external validity when referring to the design of both animal studies and clinical trials.
为全面评估对功能和结构结果的治疗效果,我们对颅内出血干细胞治疗的临床前数据进行了荟萃分析,从而为临床转化提供最佳证据和指导。我们检索在线数据库,以识别基于颅内出血(ICH)中未修饰干细胞移植的合格研究。从每项研究中,我们提取了有关神经行为和组织学结果的数据,以便根据最重要的临床参数(七个指标)分析综合效应大小,并通过荟萃回归探索任何潜在相关性。我们分析了40项合格研究,包括1021只动物,发现行为和结构结果均有显著改善,改良神经严重程度评分的中位效应大小为1.77,改良定位试验为1.16,转棒试验为1.82,组织损失减少为1.24。荟萃回归结果显示,脑内给药对ICH后行为和结构恢复最有效;间充质干细胞与神经干细胞具有相当的治疗效果。ICH后1周以上进行的延迟治疗显示结构结果改善最大。干细胞治疗对ICH动物的行为和结构结果有显著改善,效应大小相对较大。然而,考虑到研究质量差和不可忽视的发表偏倚,该治疗的实际疗效可能较低。此外,在参考动物研究和临床试验设计时,考虑到有限的内部和外部有效性,未来的研究应谨慎解释动物结果。